Archives: Agenda

• Challenges in leveraging clinical and vigilance data, leading to delays and untapped potential
• How to overcome this and make your health data available for secondary use in your organization
• How this accelerates market access and reduces workload and costs

• Learning how the agile certification process prototype harmonizes the MDR and AI Act, creating a streamlined path for innovative AI technologies to meet stringent regulatory standards
• Understanding the importance of effective change management in maintaining compliance throughout the lifecycle of AI medical devices

• Exploring ways RWD can accelerate innovation
• Regulatory, post-market surveillance and market access
• Improved patient outcomes

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within the medical devices industry.

RT1 – Tackling challenges and harnessing real-world data for medical device companies

Herbert Mauch, Director Clinical Operations EMEA, Cochlear AG

RT2 – Do Notified Bodies’ dedicated programs help or hinder new medical device manufacturers?

Karel Volenec, CEO, ELLA-CS

RT3 -Building a relationship with your study team – how to get good and timely results from everyone included

Pavel Kušnierik, Head of Regulatory Affairs, Contipro

RT4 – PMCF legacy devices: the PMCF Plan, expectations and challenges for obtaining user feedback

Yvonne Hoogeveen, Director Clinical Affairs, Wellinq

• Prediction of operational efficiency of clinical trials by machine learning models
• Prediction of early trial termination of clinical trials
• Prediction of adverse event reporting in clinical trials

• Exploring the conjunction between medical devices and digital health
• What are the success factors?
• Dos and don’ts and best practice examples